Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by DermTech, Inc.
< Previous
1
2
3
Next >
DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology
March 08, 2024
From
DermTech, Inc.
Via
Business Wire
Tickers
DMTK
DermTech Reports Fourth-Quarter 2023 Financial Results
February 29, 2024
From
DermTech, Inc.
Via
Business Wire
Tickers
DMTK
DermTech Announces Release Date for Fourth-quarter 2023 Financial Results
February 13, 2024
From
DermTech, Inc.
Via
Business Wire
Tickers
DMTK
DermTech Announces Additional Restructuring Actions to Focus on Revenue Growth and Streamline Operations
January 31, 2024
From
DermTech, Inc.
Via
Business Wire
Tickers
DMTK
DermTech Announces Positive Topline Results From a Study Evaluating the DermTech Melanoma Test (DMT) Across All Skin Types
January 18, 2024
From
DermTech, Inc.
Via
Business Wire
Tickers
DMTK
DermTech Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-on Assay
January 16, 2024
From
DermTech, Inc.
Via
Business Wire
Tickers
DMTK
DermTech Announces Positive Topline Results From Trust 2 Study Evaluating the DermTech Melanoma Test (DMT)
January 08, 2024
From
DermTech, Inc.
Via
Business Wire
Tickers
DMTK
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 14, 2023
From
DermTech, Inc.
Via
Business Wire
Tickers
DMTK
DermTech Reports Third-Quarter 2023 Financial Results
November 02, 2023
From
DermTech, Inc.
Via
Business Wire
Tickers
DMTK
DermTech Announces Release Date for Third-Quarter 2023 Financial Results
October 12, 2023
From
DermTech, Inc.
Via
Business Wire
Tickers
DMTK
DermTech Grants New CCO Mark Aguillard Inducement Award Under NASDAQ Listing Rule 5635(c)(4)
September 21, 2023
From
DermTech, Inc.
Via
Business Wire
Tickers
DMTK
DermTech Announces Contracts With Highmark for the Foundational Assay of Its DermTech Melanoma Test (DMT)
September 19, 2023
From
DermTech, Inc.
Via
Business Wire
Tickers
DMTK
DermTech Appoints Mark Aguillard as Chief Commercial Officer
September 11, 2023
From
DermTech, Inc.
Via
Business Wire
Tickers
DMTK
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 25, 2023
From
DermTech, Inc.
Via
Business Wire
Tickers
DMTK
DermTech Reports Second-Quarter 2023 Financial Results
August 03, 2023
From
DermTech, Inc.
Via
Business Wire
Tickers
DMTK
DermTech Announces Favorable Coverage Policy With Blues Plan in Michigan for the Foundational Assay of Its DermTech Melanoma Test (DMT)
July 19, 2023
From
DermTech, Inc.
Via
Business Wire
Tickers
DMTK
DermTech Announces Release Date for Second-Quarter 2023 Financial Results
July 17, 2023
From
DermTech, Inc.
Via
Business Wire
Tickers
DMTK
DermTech Adds Approximately 7 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)
July 12, 2023
From
DermTech, Inc.
Via
Business Wire
Tickers
DMTK
DermTech Announces Restructuring to Prioritize Growth Opportunities and Streamline Operations
June 28, 2023
From
DermTech, Inc.
Via
Business Wire
Tickers
DMTK
ECRI Completes Evaluation of the Pigmented Lesion Assay (PLA), the Foundational Assay for the DermTech Melanoma Test (DMT)
June 14, 2023
From
DermTech, Inc.
Via
Business Wire
Tickers
DMTK
DermTech Announces Contract With Hawaii Blues Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT)
June 07, 2023
From
DermTech, Inc.
Via
Business Wire
Tickers
DMTK
DermTech Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
June 02, 2023
From
DermTech, Inc.
Via
Business Wire
Tickers
DMTK
DermTech Surpasses 200,000 Cumulative Billable Samples for the DermTech Melanoma Test (DMT)
May 31, 2023
From
DermTech, Inc.
Via
Business Wire
Tickers
DMTK
DermTech Announces Agreements With South Carolina Blues Plan and the United Mine Workers of America Health and Retirement Funds for the Foundational Assay of Its DermTech Melanoma Test (DMT)
May 11, 2023
From
DermTech, Inc.
Via
Business Wire
Tickers
DMTK
DermTech Grants New CEO Bret Christensen Inducement Award Under NASDAQ Listing Rule 5635(c)(4)
May 10, 2023
From
DermTech, Inc.
Via
Business Wire
Tickers
DMTK
DermTech Appoints Bret Christensen as New President and CEO
May 09, 2023
From
DermTech, Inc.
Via
Business Wire
Tickers
DMTK
DermTech Reports First-Quarter 2023 Financial Results
May 04, 2023
From
DermTech, Inc.
Via
Business Wire
Tickers
DMTK
New Survey Data Reveals Nearly 75% of Consumers Have Not Had a Full Skin Exam Within the Past 12 Months
May 01, 2023
From
DermTech, Inc.
Via
Business Wire
Tickers
DMTK
DermTech Announces Contract With New York Health Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT)
April 26, 2023
From
DermTech, Inc.
Via
Business Wire
Tickers
DMTK
DermTech Announces Release Date for First-quarter 2023 Financial Results
April 13, 2023
From
DermTech, Inc.
Via
Business Wire
Tickers
DMTK
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.